Compare TMQ & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMQ | IRWD |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.5M | 741.8M |
| IPO Year | 2012 | 2009 |
| Metric | TMQ | IRWD |
|---|---|---|
| Price | $3.89 | $3.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | ★ 4.2M | 2.7M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $22.53 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.15 | $0.55 |
| 52 Week High | $11.29 | $5.78 |
| Indicator | TMQ | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 37.17 |
| Support Level | $3.79 | $3.08 |
| Resistance Level | $4.55 | $3.53 |
| Average True Range (ATR) | 0.27 | 0.28 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 7.79 | 41.36 |
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.